March 2026 Research Update

This month added stronger signals that B cell-targeting treatments can reduce flares and, in some settings, reduce reliance on glucocorticoids (steroids), while also showing how researchers are trying to measure treatment intensity and predict who relapses. One randomized trial subgroup analysis reported fewer flares on inebilizumab than on placebo, and a large real-world comparison reported that people treated with rituximab were more often able to be off steroids by 6 months. Alongside these, one cohort study linked certain lab results and higher cumulative steroid exposure with relapse and death, and a new phase 3 trial of obexelimab reached full enrollment but has not reported results yet. [1] [2] [3] [4]

In a Japanese subgroup from a phase 3 trial, inebilizumab (a B cell-depleting antibody) was compared with placebo, and the inebilizumab group had no adjudication committee-determined flares needing treatment during follow-up. In the placebo group, flares were observed in 4 of 7 people, and the study also reported more flare-free complete remission and lower glucocorticoid use with inebilizumab, with similar overall safety between groups. This supports the idea that preventing flares by targeting B cells is a realistic goal, although this subgroup was small. [1]

In routine care across three European referral centers, people treated with rituximab were more likely to be free from glucocorticoids at 6 months than those treated with glucocorticoids alone, and their 12-month cumulative prednisone dose was lower. Other response and remission measures were reported as similar between groups, even though the rituximab group appeared to have more severe disease at the start. For patients, this study adds practical evidence that some treatment plans may reduce long-term steroid exposure, while still needing careful interpretation because this was not a randomized comparison. [2]

A separate retrospective cohort tried to quantify treatment intensity using cumulative defined daily doses and relate this to relapse and survival, while also comparing a proliferative versus fibrotic subtype. The study reported that relapse was independently linked with higher ALT, higher total IgG, and greater steroid exposure, and that anemia predicted both relapse and death; it also reported links between early hydroxychloroquine use and lower initial steroid exposure with improved survival. This kind of work matters because it aims to move beyond a one-size-fits-all view of treatment, but it cannot prove cause-and-effect because it was observational. [3]

Looking ahead, the INDIGO phase 3 trial of obexelimab (an antibody designed to inhibit B cells by co-engaging two receptors) reported that enrollment reached 194 participants, but outcomes are not available yet. Its main outcome is time to first flare requiring rescue therapy over 52 weeks, which matches the practical question many patients care about: staying in remission longer with less need for additional steroids. This trial description mainly signals that a large, definitive study is underway, rather than providing new effectiveness results now. [4]

For patients and caregivers, this month most clearly adds evidence that flare prevention is being tested in multiple ways, especially by targeting B cells. One randomized subgroup analysis supports fewer flares with inebilizumab compared with placebo, while real-world data suggest rituximab can be part of a steroid-sparing approach for some people. What remains uncertain is how to match the right medicine to the right person and how these results apply across different organs and disease patterns, since some data came from small subgroups or non-randomized comparisons. This is information that may matter now when discussing the overall direction of research and care, but it does not by itself determine what any individual should use.

These studies collectively show that diagnosis in IgG4-related disease often depends on patterns seen on imaging or lab tests, but that some findings can be misleading without context. Two imaging studies suggested that whole-body PET/CT scans can be particularly helpful in suspected IgG4-related disease, and one newer PET method proposed a scoring system to separate active from inactive disease. Other work showed that a common blood test pattern (serum protein electrophoresis) can mimic a monoclonal protein signal when IgG4 is high, and that the tumor marker CA19-9 can be elevated in IgG4-related autoimmune pancreatitis in ways that overlap with concerns about pancreatic cancer. [5] [6] [7] [8]

In a tertiary rheumatology center cohort of 280 people who had 18F-FDG PET/CT for difficult diagnostic questions, the scan helped establish a new diagnosis in about 30% and prompted treatment modification in about 27%. IgG4-related disease stood out as one of the conditions where PET/CT most often contributed diagnostically, reported as diagnostic in 71.4% of IgG4-related disease cases. For patients, this supports the idea that whole-body imaging can sometimes help find involved organs or clarify what is driving inflammation, especially when the picture is unclear. [5]

A separate retrospective study evaluated a different PET tracer, 18F-FAPI PET/CT, and proposed an activity score (FPAS-IgG4) to distinguish active from inactive IgG4-related disease. The score was higher in active disease and a threshold above 2 was reported to have high sensitivity with moderate specificity for active disease, and the score was independently linked to disease activity in multivariable analysis. This matters because patients often face uncertainty about whether symptoms or imaging changes represent active inflammation versus longer-term scarring, but the study also noted the need for broader validation. [6]

A large laboratory dataset study described a distinctive serum protein electrophoresis (SPEP) pattern seen with elevated polyclonal IgG4 that can look like a monoclonal protein pattern, with immunofixation showing a pseudoclonal restriction. The pattern was uncommon (3 per 1,000 SPEPs), but more than half of newly identified elevated IgG4 cases were detected through SPEP, and about 29% had an altered free light chain ratio. For patients, this helps explain why some blood tests can raise concerns about blood cancers and then require careful follow-up testing to clarify what is really being seen. [7]

In IgG4-related autoimmune pancreatitis, a 41-person retrospective study compared those with elevated versus normal CA19-9 and found that elevated CA19-9 was linked with more frequent misdiagnosis as pancreatic cancer and more bile duct involvement, along with worse liver-related lab markers. CA19-9 correlated with bilirubin and liver enzymes, but not with IgG4 levels, and pancreatic imaging features did not significantly differ between groups. This supports a clearer message for patients: CA19-9 can rise in IgG4-AIP and may reflect bile duct and liver test changes more than it reflects IgG4 itself. [8]

For patients, the main practical update is that researchers are refining tools that may help confirm IgG4-related disease, map which organs are involved, and judge how active the inflammation is. PET/CT imaging was reported as particularly useful in IgG4-related disease in a real-world rheumatology setting, and an experimental PET-based activity score showed promising accuracy in one center. At the same time, blood test patterns (like SPEP) and markers such as CA19-9 can be confusing because they overlap with other conditions, so these studies mainly add clarity about what can cause false alarms and why additional tests are sometimes needed. Most of this evidence is observational, so it supports understanding and future research more than it provides a single definitive diagnostic shortcut today.

This month reinforced that IgG4-related disease can show up in many different organs, sometimes in unexpected ways, and that IgG4-rich inflammation can also appear in conditions that do not fully meet IgG4-related disease criteria. Several reports described nervous system and heart or blood vessel involvement, often discovered with imaging and then confirmed by biopsy when possible. Separately, pathology studies described where IgG4-positive plasma cells may signal true IgG4-related disease versus an overlap or a different condition, which matters because treatment and monitoring decisions often start with getting the diagnosis right. [9] [10] [11] [12] [13] [14]

Case reports highlighted cardiovascular involvement detected on scans even when symptoms were minimal or absent. One person with coronary arteritis had coronary wall thickening and PET uptake that improved with high-dose prednisone, but then relapsed and was treated with rituximab, underscoring that imaging may be central to detecting and tracking this type of involvement. Another report described a person with longstanding IgG4-related disease who had diffuse, high-risk coronary atherosclerosis found incidentally on coronary CT angiography, with plaque features that raised concern despite no aneurysm. [9] [10]

Nervous system involvement also appeared in this month’s reports, emphasizing both misdiagnosis risk and the potential for improvement with treatment once recognized. One report of hypertrophic pachymeningitis described a skull lesion and mass that shrank after surgery and prednisone, alongside a literature review where most treated cases had favorable outcomes. Another pachymeningitis report described relapse during steroid tapering with sustained control after rituximab, showing that some cases can be harder to keep quiet long-term. [11] [15]

A retrospective series focusing on peripheral neuropathy as the first sign of IgG4-related disease described 16 cases where nerve symptoms came before other organ involvement, and all patients had multi-organ disease identified in addition to nerve damage. Nerve testing showed mixed patterns of demyelination and axonal injury, and all reported cases responded well to oral corticosteroids, with a few also receiving other immune-suppressing medicines. For patients, this clarifies that numbness or weakness can sometimes be part of IgG4-related disease, and that identifying the broader organ pattern can be key to understanding what is happening. [12]

Two pathology-focused studies illustrated the boundary between IgG4-related disease and look-alike inflammation. In chronic gallbladder inflammation, lymphoplasmacytic cholecystitis consistently had low IgG4 features, while a small subset of xanthogranulomatous cholecystitis showed IgG4-type findings and only some met all key IgG4-related histology features, suggesting partial overlap rather than a clear diagnosis by itself. In the esophagus, a 12-person case series described chronic ulcerative esophagitis rich in IgG4-positive plasma cells that did not strictly meet IgG4-related disease criteria, yet many had partial symptom improvement with corticosteroids. [14] [13]

For patients and caregivers, these studies add a clearer picture that IgG4-related disease can affect the heart, blood vessels, and nervous system, sometimes being found mainly through imaging rather than obvious symptoms. They also show that seeing many IgG4-positive cells in a biopsy does not always equal IgG4-related disease, because some inflammatory conditions can partially overlap or mimic it. What remains uncertain is how often these rarer patterns occur and which tests best confirm them, since much of the evidence here comes from individual cases and retrospective series. This information mostly helps with understanding and awareness rather than changing treatment decisions on its own.

This month added broader context about how IgG4-related disease can differ by age and how often it overlaps with allergy-type immune features. A retrospective comparison suggested that younger and older patients may show different organ patterns, while a large meta-analysis reported that allergy history, higher eosinophils, and high IgE are common in IgG4-related disease. Together, these studies make the disease feel less like a single fixed pattern and more like a condition with recognizable clusters that may vary between people. [16] [17]

In a retrospective descriptive study comparing people diagnosed at age 25 or younger versus 50 or older, younger patients more often had ocular involvement, while older patients more often had multi-organ involvement and certain organ sites such as lymph nodes, submandibular gland, and lung. Laboratory variables were reported as not significantly different between the age groups, and biopsies commonly showed a lymphoplasmacytic infiltrate, with eosinophilic infiltrates more frequent in older patients. For patients, this helps set expectations that the same diagnosis can look different depending on age at diagnosis. [16]

A systematic review and meta-analysis across 32 studies reported that allergy was present in about 44% of IgG4-related disease patients, eosinophilia in about 22%, and hyper-IgE in about 73%. The authors noted that the reason for this overlap is still unclear and that better comparison studies are needed to know how specific these features are to IgG4-related disease. For patients, this supports a simple point: many people with IgG4-related disease also have allergy-type immune signals, but these findings are not unique to this disease. [17]

For patients, these results mainly add context about what is common in IgG4-related disease rather than offering new tests or treatments. Age at diagnosis may relate to which organs are more likely to be involved, and allergy-type features such as high IgE appear frequently across studies. What remains uncertain is whether allergy or eosinophilia changes outcomes or should be interpreted as part of the disease itself versus a coexisting condition, because the meta-analysis could not answer cause-and-effect questions. This information may matter most for understanding personal variation and for shaping future research.

Several single-patient reports this month showed how IgG4-related disease can be confirmed in unexpected tissues and how imaging and biopsy are often paired to reach a diagnosis. Across these cases, steroids were commonly reported to improve symptoms and imaging findings, but relapse could occur, and some patients needed additional immune-targeting medicines. These reports do not tell how common these situations are, but they illustrate the range of real-world presentations that can lead to diagnosis. [18] [19] [20] [21] [22] [23]

One report described diagnosis supported by a gastric mucosal biopsy showing marked IgG4-positive plasma cell infiltration, followed by rapid improvement after prednisolone and sustained improvement over 12 months. Another case described IgG4-related prostatitis detected by whole-body diffusion-weighted imaging, confirmed by targeted biopsy, and followed by improvement in symptoms, serum IgG4, and imaging signal after treatment. A third case described IgG4-related dacryoadenitis confirmed by biopsy, with rapid symptom and imaging improvement on glucocorticoids and recurrence after abrupt withdrawal that improved after restarting. [18] [19] [20]

One rare case involved IgG4-related disease affecting the carotid artery and vagus nerve, where prednisone and methotrexate were not enough and the addition of tocilizumab was followed by symptom improvement and reduction in mass size on imaging over 12 months. Another case series in people treated with efgartigimod for myasthenia gravis included a patient with IgG4-related disease among other IgG-mediated conditions, and the authors reported improvement in myasthenia gravis measures along with control of the overlapping IgG-mediated disease manifestations. These reports expand the list of immune-targeted medicines being tried in unusual situations, but they are early signals rather than proof of benefit for most patients with IgG4-related disease. [21] [22]

One case of idiopathic retroperitoneal fibrosis causing duodenal obstruction was included this month because it sits near the IgG4-related disease spectrum and illustrates a diagnostic challenge. In that report, inflammatory markers and serum IgG4 were normal, no tissue biopsy was obtained due to the lesion location, and the patient did not improve with high-dose corticosteroids. This single case underlines that blood tests alone may not capture every inflammatory fibrosing condition, and that not all similar-appearing conditions behave the same way. [23]

For patients, these case reports mainly provide concrete examples of how diagnosis and monitoring can work when the disease shows up in less typical places, such as stomach lining or the prostate, and how imaging changes can track response over time. They also show that steroid response can be rapid in some individuals, but that recurrence can happen, and that additional medicines are sometimes used when steroids are not enough. What remains uncertain is how often these situations occur and whether the same outcomes would happen in other people, because single-patient reports cannot predict average results. This information is most useful for understanding the range of possibilities rather than for drawing conclusions about what will happen to any one person.